Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6052MR)

This product GTTS-WQ6052MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6052MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14779MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ705MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ15543MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1763MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ9255MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ15314MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ14022MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ696MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW